United States

2015 Press Releases

2015 | 2014 | 2013 | 2012 | 2011 | 2010
Search News Releases
01/26/15Medtronic Completes Acquisition of Covidien
DUBLIN, Ireland - January 26, 2015 - Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, announced today that it has successfully completed the previously announced acquisition of Covidien plc (NYSE: COV). Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc.  Shares of Medtronic plc are expected to begin trading on the New York Stock Exchange (NYSE) under the symbol "MDT" on Tuesday, J... 
Download PDFPrinter Friendly Version
01/26/15Medtronic's Pending Acquisition of Covidien Approved by Irish High Court
Transaction Anticipated to Close on January 26, 2015 MINNEAPOLIS AND DUBLIN, Ireland - January 26, 2015 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the Irish High Court has sanctioned the Covidien scheme of arrangement pursuant to which Medtronic will acquire Covidien under a new holding company incorporated in Ireland to be named Medtronic plc.  With the Court's approval of the scheme of arrangement, Medtronic and Covidien anticipate that the transaction, wh... 
Download PDFPrinter Friendly Version
01/23/15Medtronic Introduces Enhanced Therapy to Treat Debilitating Symptoms of Serious Stomach Disorder
FDA-Approved System May Provide Long-Term Symptom Relief for Patients Suffering from Gastroparesis MINNEAPOLIS - January 23, 2015 -Medtronic, Inc. (NYSE: MDT) today announced it has received United States Food and Drug Administration (FDA) approval, under a humanitarian device exemption* (HDE),for the Medtronic Enterra® II System. The system is used to treat chronic, intractable (drug-refractory) nausea and vomiting associated with gastroparesis of diabetic or unknown origin when more conserva... 
Download PDFPrinter Friendly Version
01/22/15Covidien Reports First-Quarter 2015 Results
First-quarter net sales up 2% (up 6%, excluding foreign exchange rate movement) First-quarter diluted GAAP earnings per share were $1.12; excluding specified items, adjusted diluted earnings per share were $1.11 DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 22, 2015-- Covidien plc (NYSE: COV) today announced financial results for the first quarter of fiscal 2015. First-quarter net sales of $2.69 billion increased 2% ... 
Download PDFPrinter Friendly Version
01/21/15Medtronic Launches MiniMed 640G System, Breakthrough in Artificial Pancreas Technology, Outside the U.S.
New SmartGuard(TM) Technology Helps People with Diabetes Manage the Challenges of Hypoglycemia MINNEAPOLIS - January 21, 2015 - Medtronic, Inc. (NYSE:MDT) today announced the start of the global launch of the MiniMed(TM) 640G System, the next breakthrough toward an artificial pancreas.  With the introduction of Medtronic's exclusive SmartGuard(TM) technology, MiniMed 640G is designed to help people with diabetes achieve better glucose control through advanced protection from hypoglycemia. The ... 
Download PDFPrinter Friendly Version
01/16/15Medtronic Awards $150,000 Locally in Health Access Grants
Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved SANTA ANA, CALIF. - Jan. 16, 2015 - The Lestonnac Free Clinic and CHOC Children's Foundation each received a two-year Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare in Orange County.  Each organization was nominated by a team of Medtronic employees working at the Medtronic Orange County site in San... 
Download PDFPrinter Friendly Version
01/12/15Medtronic Highlights Growth Opportunities at J.P. Morgan Healthcare Conference
SAN FRANCISCO -- Jan. 12, 2015 -- Chairman and CEO Omar Ishrak discussed the future of Medtronic, Inc. (NYSE: MDT) during a presentation to investors at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco today.  The presentation outlined the company's continued focus on creating long-term value in healthcare through its three key strategies of therapy innovation, globalization and economic value. The pending acquisition of Covidien was also highlighted, which is expected to close... 
Download PDFPrinter Friendly Version
01/12/15Medtronic Awards $150,000 Locally in Health Access Grants
Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved Goleta, CA - January 12, 2015 - Santa Barbara Neighborhood Clinics, Direct Relief and Jodi House Brain Injury Support Center each received a two-year $50,000 Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare.  Each was nominated by a team of Medtronic Neurosurgery employees working in Goleta, CA. The... 
Download PDFPrinter Friendly Version
01/08/15Medtronic-Sponsored European Clinical Trial to Evaluate Cryoballoon Ablation as First-Line Treatment for Patients with Symptomatic Paroxysmal Atrial Fibrillation
MINNEAPOLIS - Jan. 8, 2015 - Medtronic, Inc., (NYSE:MDT) today announced the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Arctic Front Advance(TM) cryoballoon as a first-line treatment for atrial fibrillation (AF) patients. While medication is currently considered first-line treatment for AF, clinical research indicates that half of all patients with symptomatic disease do not respond to drug therapy1; earlier ablation may improve tre... 
Download PDFPrinter Friendly Version
01/07/15New Clinical Trial Will Evaluate Antibacterial Envelope in Cardiac Implantable Electronic Device Patients at Risk for Major Infections
Medtronic Announces First Patient Enrollment in the WRAP Infection Clinical Trial MINNEAPOLIS - Jan. 7, 2015 - Medtronic, Inc. (NYSE: MDT)  today announced the first patient enrollment in the WRAP Infection Clinical Trial, which will evaluate the effectiveness of the TYRX(TM) Absorbable Antibacterial Envelope in reducing major infections in patients with cardiac implantable electronic devices (CIEDs) at risk for infection. The global clinical trial also will assess healthcare costs related to t... 
Download PDFPrinter Friendly Version
01/06/15Medtronic Shareholders Approve Proposals Related to Medtronic's Acquisition of Covidien
MINNEAPOLIS - Jan. 6, 2015 - Medtronic, Inc. (NYSE: MDT) announced that all proposals related to Medtronic's acquisition of Covidien were approved by Medtronic's shareholders today.  Based on preliminary vote results, the proposal to adopt the transaction agreement and approve the merger was approved by shareholders owning approximately 95.66 percent of the shares voted at the meeting and approximately 75.18 percent of the outstanding Medtronic shares as of the record date.  The final vote resu... 
Download PDFPrinter Friendly Version
01/06/15Announcement under Irish Takeover Rules -- Results of Covidien plc's Shareholder Meetings
This Announcement is Being Made Solely to Comply with the Requirements of the Irish Takeover Rules. the Information Set out Herein Concerning the Results of Covidien plc's Shareholder Meetings on January 6, 2015 Will Also Be Set out in Covidien plc’s Form 8-K to Be Filed on January 6, 2015 DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 6, 2015-- On January 6, 2015, Covidien plc, a public limited company organized under the laws of Ireland, held a spec... 
 Printer Friendly Version
01/05/15Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
MINNEAPOLIS - Jan 5, 2015 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 33rd annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, in San Francisco. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about Medtronic beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 12, 2015, by clicking on the Investo... 
Download PDFPrinter Friendly Version
01/05/15Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg
Pivotal Study Shows New Medical Device Provides Exceptional Clinical Outcomes and Reduces Need for Costly Repeat Procedures MINNEAPOLIS -- Jan. 5, 2015 -- Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's IN.PACT Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) in the upper leg, a serious and common cardiovascular condition that causes pain in the legs and is known to be a... 
Download PDFPrinter Friendly Version

Social Media